BRÈVE publiée le 02/02/2026 à 15:41, il y a 1 mois 2 jours L'émission obligataire de 950 millions d'euros de CHEPLAPHARM est un succès Stratégie Financière Emission D'obligations Refinancement Demande Des Investisseurs CHEPLAPHARM
BRÈVE publiée le 02/02/2026 à 15:41, il y a 1 mois 2 jours CHEPLAPHARM's Successful €950m Bond Issuance Refinancing Bond Issuance Financial Strategy Investor Demand CHEPLAPHARM
COMMUNIQUÉ DE PRESSE publié le 02/02/2026 à 15:36, il y a 1 mois 2 jours Successful Refinancing: CHEPLAPHARM'S new 6.750% Bond multiple times oversubscribed CHEPLAPHARM successfully refinances with new 6.750% bond oversubscribed multiple times, enhancing financial flexibility and maturity profile Refinancing Oversubscribed Financial Flexibility CHEPLAPHARM 6.750% Bond
BRÈVE publiée le 27/08/2025 à 13:34, il y a 6 mois 8 jours CHEPLAPHARM annonce une croissance stable au premier semestre 2025 Croissance Des Revenus Industrie Pharmaceutique CHEPLAPHARM Programme De Transformation Expansion Des Employés
BRÈVE publiée le 27/08/2025 à 13:34, il y a 6 mois 8 jours CHEPLAPHARM Reports Stable Growth in the First Half of 2025 Pharmaceutical Industry Revenue Growth Transformation Program CHEPLAPHARM Employee Expansion
COMMUNIQUÉ DE PRESSE publié le 27/08/2025 à 13:29, il y a 6 mois 8 jours CHEPLAPHARM with stable business in the first half of 2025 Cheplapharm AG reports stable business performance in the first half of 2025, with revenue up by 12% and EBITDA up by 24% compared to the second half of 2024 Financial Results Transformation Program Stability Acquisition Opportunities Cheplapharm AG
BRÈVE publiée le 26/06/2025 à 10:36, il y a 8 mois 8 jours L'obligation de 750 millions d'euros de CHEPLAPHARM connaît une forte demande et un prix attractif Obligations Confiance Des Investisseurs Médicaments Flexibilité Financière CHEPLAPHARM
BRÈVE publiée le 26/06/2025 à 10:36, il y a 8 mois 8 jours CHEPLAPHARM's €750M Bond Sees High Demand and Attractive Pricing Pharmaceuticals Investor Confidence Financial Flexibility Bonds CHEPLAPHARM
COMMUNIQUÉ DE PRESSE publié le 26/06/2025 à 10:31, il y a 8 mois 8 jours High Demand and Attractive Pricing: CHEPLAPHARM's New 7.125% Bond Multiple Times Oversubscribed CHEPLAPHARM successfully places €750m senior secured notes at 7.125% interest rate, enhancing financial flexibility and extending maturity profile, oversubscribed transaction Senior Secured Notes Oversubscribed Financial Flexibility CHEPLAPHARM 7.125%
BRÈVE publiée le 02/06/2025 à 10:34, il y a 9 mois 2 jours Sandra Schröder Joins CHEPLAPHARM as VP Scientific Pharmaceutical Regulatory Affairs Quality Management CHEPLAPHARM Sandra Schröder
Publié le 04/03/2026 à 23:50, il y a 8 heures 48 minutes Capital et droits de vote au 28 février 2026
Publié le 04/03/2026 à 23:00, il y a 9 heures 38 minutes Pinetree Capital Ltd Announces Audited Financial Results for the Year Ended December 31, 2025 and Director Appointment
Publié le 04/03/2026 à 22:55, il y a 9 heures 43 minutes Pacific Avenue Capital Partners Completes Acquisition of U.S. Power Chain Hoist and Chain Business from Columbus McKinnon and Launches New Standalone Company, Stuart Rush
Publié le 04/03/2026 à 22:45, il y a 9 heures 53 minutes Viemed Healthcare Announces Record 2025 Financial Results
Publié le 04/03/2026 à 22:40, il y a 9 heures 58 minutes Stabilis Solutions Announces Fourth Quarter and Full Year 2025 Results
Publié le 05/03/2026 à 08:05, il y a 33 minutes Absa and Thunes unveil Absa Global Pay, a next-generation solution for fast, affordable global remittances
Publié le 05/03/2026 à 08:00, il y a 38 minutes RM plc: Final Results for the year ended 30 November 2025
Publié le 05/03/2026 à 08:00, il y a 38 minutes Pyrum receives ISCC EU certification for thermolysis oil – End-of-life tire recycling becomes biofuel-compatible and strengthens Europe's more resilient raw material and energy supply
